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dition, numbers of extravascular CD3+ T cells were corre-
lated with amyloid (6E10 staining) and tau pathology (AT8 
staining) in the same sections.  Results: Several CD3+, extra-
vascular T cells were observed in the brains of AD patients, 
mostly of the CD8+ subtype. AD hippocampi harbored sig-
nificantly increased numbers of extravascular CD3+ T cells 
compared to nondemented controls. CD3+ T cells signifi-
cantly correlated with tau pathology but not with amyloid 
plaques in AD samples.  Conclusions: Our data support the 
notion of T-cell occurrence in AD brains and suggest that, in 
advanced stages of AD, T-cell extravasation is driven by tau-
related neurodegenerative changes rather than by cerebral 
amyloidosis. T cells could be crucial for driving the amyloid-
independent phase of the AD pathology. 
 © 2018 S. Karger AG, Basel 
 Introduction 
 Alzheimer disease (AD), the leading cause of dementia 
in the elderly, is a complex, multifactorial disease with a 
strong inflammatory component  [1] . While the role of 
microglial cells (the resident immune cells of the brain) 
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 Abstract 
 Background: Strong genetic and epidemiological evidence 
points to a crucial role of the immune system in the devel-
opment of Alzheimer disease (AD). CD3+ T lymphocytes 
have been described in brains of postmortem AD patients 
and in transgenic models of AD-like cerebral amyloidosis 
and tau pathology. However, the occurrence of T cells in AD 
brains is still controversial; furthermore, the relationship 
between T cells and hallmarks of AD pathology (amyloid 
plaques and neurofibrillary tangles) remains to be estab-
lished.  Objectives: We have studied the occurrence of T cells 
in postmortem hippocampi and mid frontal gyrus (MFG) 
samples of AD patients (Braak stage V–VI) and nondement-
ed control subjects and correlated it with amyloid and tau 
pathology burden.  Methods: Confocal microscopy and 
bright-field immunohistochemistry were used to identify 
brain-associated T cells. Extravascular CD3+ T cells were 
quantified and compared to nondemented controls. In ad-
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has been actively studied, very little is known about the 
contribution of additional immune cells, such as T lym-
phocytes, to AD pathology  [2, 3] . 
 In fact, in contrast with the original concept of being 
an immune-privileged organ, it is becoming increasingly 
clear that the brain is under tight control by the periph-
eral adaptive immune system  [4] , which is crucially in-
volved in maintaining adult neurogenesis  [5, 6] as well as 
mounting immune reactions during challenge  [7] . In-
deed, while they are normally absent from the brains of 
healthy, young individuals, parenchymal CD3+ T cells 
have been consistently described in postmortem brains of 
AD patients  [8–11] .
 The occurrence and significance of T cells in AD brains 
is still controversial; furthermore, the relationship be-
tween T cells and hallmarks of AD (extracellular deposits 
of β-amyloid peptide (Aβ) and intracellular aggregates of 
abnormally phosphorylated tau) remains to be estab-
lished. Here, we have reassessed the occurrence of T cells 
in postmortem AD brains and correlated it with markers 
of tau and amyloid pathology.
 Materials and Methods 
 Cases 
 Paraffin-embedded hippocampal tissue blocks of 10 nonde-
mented and 9 AD cases (Braak stage V–VI) were obtained from 
the Netherlands Brain Bank (NBB), Netherlands Institute for Neu-
roscience, Amsterdam, The Netherlands. For some of the indi-
viduals, mid frontal gyrus (MFG) samples were also available (AD, 
 n = 5; non-demented,  n = 8). All material was collected from do-
nors for or from whom a written informed consent for a brain au-
topsy and the use of the material and clinical information for re-
search purposes had been obtained by the NBB. The subjects’ clin-
ical characteristics are presented in  Table 1 .
 Immunohistochemistry 
 Confocal Microscopy. Following standard deparaffinization 
and rehydration steps, hippocampal AD brain paraffin sections 
(20-μm thick) were pretreated with citrate antigen retrieval buffer 
for 20 min at 95  °  C as previously published  [12] . Subsequently, the 
sections were immune-blocked and incubated with either biotinyl-
ated GSL I-isolection B4 diluted 1: 500 (B-1205; Vector Laborato-
ries/Reactolab SA, Servion, Switzerland) and rabbit anti-human 
CD3 antibody diluted 1: 200 (A0452; DAKO Switzerland, Baar, 
Switzerland) or biotinylated GSL I-isolection B4 and rabbit anti-
human CD8 antibody diluted 1: 400 (108R-16; Cell Marque, Rock-
lin, CA, USA) for 2 h at RT. The sections were subsequently incu-
bated with Cy2-conjugated streptavidin (diluted 1: 800; Jackson 
ImmunoResearch/Milan Analytica AG, Rheinfelden, Switzerland) 
and Cy3-conjugated donkey anti-rabbit secondary antibody (di-
luted 1: 700; Jackson ImmunoResearch/Milan Analytica AG) for 
1 h at room temperature, followed by incubation with DAPI di-
luted 1: 5,000 for 5 min at RT and 0.2% Sudan Black in 50% ethanol 
for 10 min at room temperature. The sections were coverslipped 
using Hydromount ® mounting medium (National Diagnostics, 
Atlanta, GA, USA).
 z-stack images of the stained sections were acquired at an emis-
sion and excitation wavelength of 405, 488, and 561 nm and 460, 
520, and 570 nm for DAPI, Cy2, and Cy3, respectively, using con-
focal microscopy (Leica SP8; Leica, Wetzlar, Germany) in sequen-
tial imaging mode. The acquired images were converted into max-
imum z-stack projection images and 3-D volume renderings of the 
maximum z-stack projections in ImageJ (National Institutes of 
Health, Bethesda, MD, USA).
 Double Bright-Field Immunohistochemistry and 6E10 Staining 
of Plaques. Sections (5 μm thick) were deparaffinized and rehy-
drated. Following antigen retrieval with citrate buffer and protein-
ase K, the sections were blocked in 10% donkey serum in TBS-T 
for 1 h at room temperature and incubated with rabbit anti-human 
CD3 antibody (A0452; DAKO, Glostrup, Denmark) for 2 h at RT. 
Afterwards they were incubated with secondary biotinylated don-
key anti-rabbit antibody and further processed using the Vecta-
Stain ® Elite staining and nickel-enhanced DAB substrate. The sec-
tions were subsequently incubated with mouse anti-human colla-
gen IV antibody (M0785; DAKO, Glostrup, Denmark) for 2 h at 
RT and processed as described for the CD3 staining, with the use 
of nonenhanced DAB substrate. Hippocampal and MFG sections 
adjacent to the ones stained for CD3 and collagen IV were pro-
cessed and incubated with rabbit anti-human CD3 and mouse an-
ti-human phospho-tau antibody (AT8, diluted 1: 200; Fisher Sci-
entific, Wohlen, Switzerland) as described above using nickel-en-
Table 1.  Patient characteristics
Nondemented 
controls
Alzheimer 
disease 
patients
Subjects, n (% females) 10 (60) 9 (100)
Age, years 84 ± 1.9 84.1 ± 3.6
APOE status
3/2 1 (10) 0
3/3 6 (60) 3 (33.3)
3/4 2 (20) 4 (44.4)
4/4 0 2 (22.2)
u.d. 1 (10) 0
CERAD
0 2 (20) 0
A 6 (60) 0
B 2 (20) 0
C 0 9 (100)
Braak stage
1 7 (70) 0
2 2 (20) 0
3 1 (10) 0
4 0 0
5 0 3 (33.3)
6 0 6 (66.7)
 Values are presented as numbers (%) or means ± SD unless 
otherwise stated. CERAD, Consortium to Establish a Registry for 
Alzheimer’s Disease; u.d., undetermined.
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hanced and nonenhanced DAB as a substrate for the tau and CD3 
staining, respectively. Another set of adjacent sections was incu-
bated with mouse anti-Aβ 6E10 antibody (diluted 1: 500; Lucerna-
Chem, Luzern, Switzerland) as described above. Microscopy im-
ages were acquired from the Aβ-, tau-, CD3-, and collagen IV-
stained sections using a Leica DM4000B microscope (Leica) 
equipped with an Olympus DP71 digital camera (Olympus, 
Volketswil, Switzerland) in bright-field (tau-, CD3-, and collagen 
IV-stained sections) or fluorescent (Aβ-stained sections) mode. 
 Quantification  
 The number of Aβ plaques, paired helical filament tau-positive 
structures (including neurofibrillary tangles, tau-positive perycar-
ia and neuritic plaques, as shown in Fig. 2A), and intra- and extra-
vascular CD3+ T cells was quantified with a ×20 objective using 
the newCAST module of Visiopharm software (Visiopharm, Hør-
sholm, Denmark). A region of interest was drawn around the en-
tire section and the automatic stage was set to randomly move 
within the region of interest, covering 50% of the section’s area. 
CD3- and tau-positive cells and Aβ plaques were counted by the 
experimenter, blind to the origin of the samples and normalized to 
the size of the respective brain section.
 Statistical Analysis  
 Two-way ANOVA was used to study the effect of brain region 
and diagnosis on numbers of CD3+ T cells. Bonferroni post hoc 
multiple comparisons were used to determine statistically signifi-
cant differences. Correlations were analyzed with Pearson’s cor-
relation test and coefficients of determination ( R 2 ) of linear regres-
sion were calculated (all analyses were performed with Prism ver-
sion 5.0) 
 Online Supplementary Methods 
 See www.karger.com/doi/10.1159/000486200 for all online 
suppl. material.
 CD3/CD8 Quantification Study . For this study we used 5-μm-
thick hippocampal sections from 9 subjects (4 nondemented con-
trols and 5 AD patients). The sections (2 per subject) were pro-
cessed as indicated above for confocal immunofluorescence stain-
ing. The primary antibodies used were: rabbit anti-CD3 (A0452; 
DAKO, Glostrup, Denmark; working dilution 1: 200), mouse anti-
human CD8 alpha (ab17147; Abcam, USA; working dilution 1: 50), 
and donkey anti-mouse Cy3 and anti-rabbit Alexa488 (both from 
Jackson Laboratories, USA; working dilution 1: 200). For quantifi-
cation, 10 microscopy images (5 for CD8 and 5 for CD3) were ac-
quired from each section using a Leica DM4000B microscope (Lei-
ca) equipped with an Olympus DP71 digital camera (Olympus, 
Volketswil, Switzerland). CD3+ and CD8+ cells were manually 
counted in each image; the numbers were added up to generate the 
total number of CD3+ and CD8+ cells per subject per slide. Data 
are shown as the percentage of CD8+ cells over the total number 
of CD3+ cells.
 Granzyme B and Caspase 3 Study.  The staining protocol was 
optimized on human, formalin-fixed, and paraffin-embedded ton-
sil material, which was obtained anonymized from the tissue bio-
bank of the Institute of Pathology and Molecular Pathology, Uni-
versity Hospital Zürich. The primary antibodies used were: mouse 
anti-human granzyme B (clone GBZ01; Thermo Fisher Scientific, 
USA; working dilution 1: 50) and rabbit anti-cleaved caspase 3 
(Cell Signaling, USA; working dilution 1: 300). 
 Results 
 Increased Occurrence of T Cells in Postmortem AD 
Brain Parenchyma 
 To reassess the occurrence of T cells in AD brains, we 
first used hippocampal samples from advanced AD stage 
subjects (Braak stages V and VI), as these have been de-
scribed to harbor the highest number of cerebral T cells 
 [10] . Triple immunostainings were used to identify CD3+ 
or CD8+ T cells with respect to endothelial cells (stained 
with isolectin 4) or astrocytes (GFAP).
 Several extravascular CD3+ T cells were observed in 
the samples ( Fig.  1 A–C); on average, 90% of all of the 
CD3+ T cells observed were CD8+ (see online suppl. 
Fig. 1A, B). The morphology of CD3+ T cells varied great-
ly; most cells showed a typical small and round-shaped 
morphology, but we also observed cell protrusions con-
sistent with uropod formation and large cells with an in-
tense cytoplasmic CD3 signal ( Fig. 1 B). Even though such 
morphologies could suggest activation of infiltrated T 
cells, no granzyme B (typical marker of effector CD8+ T 
cells) was detectable in brain AD tissue, while it was read-
ily observed in human tonsils (see online suppl. Fig. 1C 
and data not shown). Furthermore, cleaved caspase 3 was 
not observed in AD brain samples, in contrast to the clear 
staining obtained in human tonsil samples (see online 
suppl. Fig. 1C and data not shown).
 Next, the numbers of CD3+ T cells were quantified in 
paired hippocampal and MFG postmortem brain sam-
ples from advanced AD (Braak stage V–VI) subjects and 
nondemented age-matched controls. We used double 
bright-field immunohistochemistry to detect T cells 
(CD3+) and vessels (stained with collagen IV). Although 
extravascular CD3+ T cells were detected in all samples 
( Fig. 1 C), their numbers were significantly increased in 
AD brains compared with those in controls ( Fig.  1 C, 
2-way ANOVA,  p < 0.05), and specifically in hippocam-
pi (Bonferroni’s post hoc test,  p < 0.01), as previously 
shown  [10] . Increased numbers of infiltrated CD3+ T 
cells were observed in hippocampi of AD cases as com-
pared to nondemented controls, regardless of the ApoE 
genotype (see online suppl. Fig. 1D). The number of T 
cells in MFG was not statistically different between AD 
and controls.
 Correlation with Pathology 
 To explore the relationship between T-cell invasion 
and AD pathology, we assessed the amyloid burden (as 
indicated by the number of 6E10+ plaques) and paired-
helical filament tau (measured by AT8+ immunoreactive 
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structures, including neuritic plaques, perikarya, and tan-
gles) in each sample ( Fig. 2 A). As expected  [13] tau pa-
thology was very rare in nondemented cases, with the hip-
pocampus more affected than the MFG. In contrast, AD 
cases and in particular AD hippocampi had a very severe 
tau pathology. Two-way ANOVA confirmed that the tau 
pathology burden was significantly affected by diagnosis 
and brain region (effect of diagnosis and brain region: 
Control
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 Fig. 1. Occurrence of CD3+ extravascular T cells in Alzheimer dis-
ease (AD) brains.  A Representative confocal microscopy maxi-
mum z-stack projection images showing hippocampus-infiltrated 
CD3+ ( i ,  ii ) and CD8+ ( iii ,  iv ) T cells in 20-μm-thick sections from 
a Braak stage VI Alzheimer disease subject. T cells were located 
outside the lumen of vessels (v, revealed with isolectin B4 staining), 
confirming their infiltration into brain parenchyma.  ii and  iv are a 
3-D volume rendering of the maximum z-stack projection shown 
in  i and  iii , respectively, identifying the presence of a nucleus 
within the structure stained by the anti-CD3 and CD8 antibodies. 
Scale bars, 10 μm.  B Representative confocal microscopy maxi-
mum z-stack projection images illustrating the heterogeneity of T 
cells detected in AD brains. Astrocytes (GFAP staining) are shown 
for comparison. Together with small, round, resting T cells with 
typical membrane-associated CD3 staining ( iii ), we also observed 
cell protrusions consistent with uropod formation ( ii , asterisk) and 
large cells with an intense cytoplasmic CD3 signal ( i ,  iv ) indicative 
of activation. Scale bars, 10 μm.  C Representative micrographs il-
lustrating T-cell occurrence (CD3, dark brown stain, arrows) in 
relation to vessels (collagen IV, light brown) in 5-μm-thick sec-
tions of hippocampi and mid frontal gyrus (MFG) from AD pa-
tients and nondemented controls. Scale bar, 200 μm. CD3+ T cells 
were found to be upregulated in AD hippocampi ( * *    p < 0.01, 
2-way ANOVA with Bonferroni’s post hoc test;  n = 9, AD;  n = 10, 
nondemented controls), but not MFG ( n = 5, AD;  n = 8, nonde-
mented controls), compared to nondemented controls. ns, not sig-
nificant. 
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 p < 0.001; diagnosis × brain region interaction:  p < 0.001; 
 Fig.  2 B). Hippocampi displayed significantly more tau 
pathology than MFG samples, an effect that was highly 
significant in AD cases ( p < 0.001, Bonferroni’s post hoc 
test;  Fig. 2 B) and is in line with the typical temporal pro-
gression of tau pathology in neurodegeneration  [14] .
 In contrast, several amyloid plaques were observed in 
hippocampi and MFG of both AD and nondemented cas-
es ( Fig. 2 A). Even though MFG from AD cases tended to 
have a higher amyloidosis than nondemented controls, a 
2-way ANOVA did not identify any statistical difference 
in amyloid burden due to brain region or diagnosis 
( Fig. 2 B).
 When we studied the correlation between the number 
of extravascular CD3+ T cells in each sample and either 
amyloid or tau pathology, we found that, overall, T cells 
significantly correlated with tau pathology ( Fig. 2 C;  p < 
0.001, Pearson’s correlation,  R 2 = 0.56) but not with the 
number of Aβ plaques. We further explored the contribu-
tion of diagnosis and brain region to this correlation. We 
found that CD3+ T cells significantly correlated with tau, 
but not with amyloid, in AD samples analyzed separately; 
here, the correlation was mostly driven by the hippocam-
pal samples ( p < 0.001, Pearson’s correlation,  R 2 = 0.55). 
In contrast, in nondemented cases analyzed as a separate 
group, we observed an overall weak correlation with am-
yloid pathology ( p < 0.05, Pearson’s correlation,  R 2 = 
0.22) while no effect of tau was detected. Even though a 
similar trend was observed in both the hippocampi and 
the MFG of nondemented patients, none of the correla-
tions reached significance when the brain areas were ana-
lyzed individually.
 Interestingly, no physical association was observed be-
tween T cells and tau costained on the same section.
 Discussion 
 Our findings add to a consistent body of evidence in 
the literature, indicating increased T cells, mostly CD8+ 
lymphocytes, in brain parenchyma of AD  [8–10] . In ad-
dition, several studies have indicated alterations in both 
peripheral and CNS-associated T cells in AD patients 
compared to controls. An increased Aβ-specific CD4-T-
cell response was found in blood-derived samples from 
AD patients, suggesting that T cells can sense the AD 
pathology  [15] . Two recent studies identified a proin-
flammatory, T-cell-mediated profile in CSF of AD pa-
tients  [16] and of amnestic MCI  [17] , a condition con-
sidered prodromal to AD. In addition, white-matter-as-
sociated T cells (largely of the CD8+ type) have been 
observed via immunohistochemistry and flow-cytome-
try in white matter from AD and other neurological dis-
eases  [18] .
 T-cell activation in the periphery and infiltration into 
the CSF and brain could therefore be an important player 
in the AD pathology. In spite of their low numbers, pa-
renchymal T cells might be able to significantly impact 
the CNS milieu by releasing pro- or anti-inflammatory 
cytokines; since the vast majority of CD3+ T cells were 
CD8+ (see online suppl. Fig. 1A, B), direct cytotoxic ac-
tivity might take place. Even though we observed mor-
phological signs of activation ( Fig. 1 B), we did not detect 
expression of granzyme B in the brain (see online suppl. 
Fig. 1C and data not shown), indicating a low overall ef-
fector function of CD8+ T cells. While the exact pheno-
type of infiltrated T cells in AD brains remains to be care-
fully characterized, based on our data we conclude that 
infiltrated CD8+ T cells are not inducing granzyme-B-
mediated apoptosis of target cells; this view is supported 
by the lack of cleaved caspase-3 expression in our sample 
set (see online suppl. Fig. 1C and data not shown). We 
speculate that initial activation of T cells is needed for 
their extravasation and infiltration into the brain paren-
chyma; once in the tissue, the cells likely downregulate 
activation markers. Previous studies in human  [10, 18] 
and animal models  [19] have indeed revealed an inhibited 
phenotype of brain-infiltrated T cells.
 It is still unclear what drives T-cell cerebral infiltration 
in AD. Misfolded amyloid and tau can independently 
lead to T-cell extravasation as shown in transgenic animal 
models of cerebral amyloidosis  [19] and tau pathology 
 [20] . However, in line with previous reports  [10, 19, 20] 
we observed no physical association between T cells and 
either amyloid deposits or tau lesions, suggesting that T 
cells are not specifically attracted to them. It is rather like-
ly that T-cell infiltration is a downstream event of AD 
neuropathology, following microglial and endothelial ac-
tivation and vascular remodeling. Since both amyloid 
 [21] and tau  [22] can induce microglial activation, mi-
croglial release of chemokines such as CCL5 (RANTES), 
CCL4 (MIP-1β), and CCL2 (MCP-1) might drive T-cell 
recruitment to AD brains (as proposed in multiple scle-
rosis  [23] ). Inflammatory chemokines might also be ex-
pressed by activated endothelial cells; indeed endothelial 
activation has been shown to occur in AD  [24] and to ac-
company amyloid pathology and T-cell infiltration in the 
context of cerebral amyloidosis in animal models of AD-
like amyloidosis  [19] . Finally, tau pathology has been re-
cently shown to affect vessel wall remodeling of lepto-
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meningeal arteries  [25] ; tau-induced arterial smooth 
muscle and elastin loss might underlie vascular frailty, 
microvessel instability, and increased permeability at the 
pre- and postcapillary level. In addition, the ApoE allelic 
state might modulate T-cell infiltration. Even though our 
sample set did not allow for a proper statistical analysis of 
data stratified by ApoE genotype, it appeared that ApoEε4 
homozygous AD cases harbored the highest number of 
infiltrated T cells as compared to the other genotypes (see 
online suppl. Fig.  1D). The effect of ApoEε4 on T-cell 
numbers might depend on the interaction with cardio-
vascular comorbidities (which can weaken the blood-
brain barrier and are associated with AD diagnosis in 
ApoEε4 carriers  [26] ) or on exacerbated tau pathology, as 
indicated in recent studies  [27] . 
 Our analysis allowed us to collect correlative evidence 
of the relationship between CD3+ T cells and AD lesions 
in postmortem human brain samples. Since CD8+ cells 
represented 90% of CD3+ T cells detected in brains, the 
correlations generated for CD3+ T cells are largely repre-
sentative of the CD8+ T cell population. However, de-
tailed quantifications of each cellular subset (CD4+ and 
CD8+) with both tau and amyloid pathology would be of 
interest and should be addressed in future studies.
 Overall, we found that the number of extravascular 
CD3+ T cells correlated with tau, but not with amyloid 
pathology. However, we found that this correlation high-
ly depended on the diagnosis and the brain region ana-
lyzed ( Fig. 2 C). Indeed, the correlation was very strong in 
AD cases, and specifically in hippocampi. The correlation 
with tau likely explained why T cell extravasation was 
more pronounced in AD hippocampi, harboring a more 
advanced tau pathology than the MFG ( Fig. 2 A, B and 
Togo et al.  [10] ).
 Our data are in line with those of Zotova et al.  [28] , 
who found that the total (i.e., intravascular and parenchy-
mal) CD3+ T cells correlated with tau, but not Aβ 1–42, 
in the superior and middle temporal gyrus, MFG and in-
ferior parietal lobule of nonimmunized AD patients. In 
addition, T-cell invasion has been observed in frontotem-
poral dementia cases  [20] , strongly indicating a link be-
tween tau degeneration and T-cell invasion.
 In contrast to what we observed in the AD brain sam-
ples, no correlation was found between T cells and tau 
pathology in nondemented controls, where instead a 
weak correlation existed with cerebral amyloid. It is im-
portant to note that although the nondemented control 
samples we analyzed displayed little to no tau pathology 
(as expected for early Braak stages), they harbored a high 
amyloid burden in both the hippocampus and the MFG. 
This finding was surprising, since the nondemented cas-
es were rated as Consortium to Establish a Registry for 
Alzhei mer’s Disease (CERAD) A and B (corresponding 
to sparse and moderate frequencies of neuritic plaques, 
respectively). However, it should be noted that the hip-
pocampus (where amyloid burden was almost identical 
between AD cases and controls) is not an area used for 
CERAD scoring. On the other hand, a nonsignificant 
trend towards a higher amyloidosis in AD cases was 
found in the MFG, as expected; the low number of sub-
jects included in this study is likely the cause of missed 
statistical significance. Therefore, in this study we lacked 
a pure, pathology-free control group. However, our sam-
ple set might allow analysis of the effect of amyloid pa-
thology alone (as seen in nondemented control subjects) 
versus amyloid-induced neurodegeneration. In this sce-
nario, our data would indicate that cerebral amyloidosis 
is only weakly associated with T-cell infiltration (as seen 
in nondemented control samples); however, once neuro-
degeneration is in place, tau-dependent T-cell invasion 
will ensue. Further studies are warranted to test this hy-
pothesis.
 Fig. 2. CD3+ extravascular T cells correlate with tau pathology in 
Alzheimer disease (AD) brains.  A Representative micrographs il-
lustrating tau (AT8 antibody) and Aβ (6E10 antibody) pathology 
across brain regions of the same individual with AD. Examples of 
neuritic plaques (indicated by the arrowhead) and AT8-positive 
perikarya (arrows) are shown. Scale bars, 50 μm (AT8) and 100 μm 
(6E10).  B Quantification of Aβ (expressed as numbers of 6E10-
positive plaques) and tau (expressed as numbers of AT8-positive 
structures) in the hippocampi and mid frontal gyrus (MFG) of AD 
and control, nondemented samples. Tau pathology was signifi-
cantly higher in AD samples compared to controls ( p < 0.01, 
2-way-ANOVA;  p < 0.05 in MFG,  p < 0.001 in hippocampi, Bon-
ferroni’s post hoc comparison). Hippocampi displayed a more se-
vere tau pathology than MFG in AD samples ( * * *   p < 0.001, 2-way-
ANOVA with Bonferroni’s multiple comparisons). Amyloid pa-
thology did not significantly differ across samples.  C Correlation 
analysis of numbers of extravascular CD3+ T cells with Aβ (ex-
pressed as numbers of 6E10-positive plaques) and tau (expressed 
as numbers of AT8-positive structures) pathology in AD samples 
and nondemented controls, hippocampi, and MFG. The correla-
tion is shown for all samples (hippocampi + MFG, AD and con-
trols), as well as divided by diagnosis (rows) and brain region (col-
umns). T-cell numbers significantly correlated with the number of 
AT8 immunoreactive structures in all of the samples ( p < 0.001, 
Pearson’s correlation). Brain area- and diagnosis-specific effects 
were observed. ns, not significant. 
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 Conclusions 
 Low-grade CD3+ T-cell infiltration occurs in AD 
brains and is more pronounced in the hippocampi than 
in the MFG. Since the number of T cells in each sample 
correlated with tau, but not with amyloid pathology, we 
propose that T-cell invasion belongs to the cascade of 
pathophysiologic events that follow Aβ-induced neuro-
degeneration at early Braak stages, but become progres-
sively Aβ-independent in AD  [29] . Elucidating the inter-
action between neuronal degeneration and T cells might 
yield novel biomarkers for disease progression and tar-
gets for therapeutic intervention.
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